

# An evaluation of an adapted United States model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland

|                                        |                                                               |                                                      |
|----------------------------------------|---------------------------------------------------------------|------------------------------------------------------|
| <b>Submission date</b><br>21/09/2006   | <b>Recruitment status</b><br>No longer recruiting             | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>17/10/2006 | <b>Overall study status</b><br>Completed                      | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>11/07/2011       | <b>Condition category</b><br>Mental and Behavioural Disorders | <input type="checkbox"/> Statistical analysis plan   |
|                                        |                                                               | <input checked="" type="checkbox"/> Results          |
|                                        |                                                               | <input type="checkbox"/> Individual participant data |

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Carmel M Hughes

### Contact details

School of Pharmacy  
Medical Biology Centre  
97 Lisburn Road  
Belfast  
United Kingdom  
BT7 9BL

## Additional identifiers

### Protocol serial number

EAT2528/03

## Study information

Scientific Title

**Acronym**

Fleetwood (N.I.) Project

**Study objectives**

This project aims to answer the following questions:

1. Can an adapted US model of care (the Fleetwood model) improve psychoactive prescribing and reduce falls in nursing home residents in Northern Ireland?
2. Does healthcare resource usage (i.e. direct healthcare costs) change as a result of the implementation of the Fleetwood model?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethical approval for the study has been obtained from the Research Ethics Committee 2 of the Office for the Research Ethics Committees, Northern Ireland, date of approval: 15th August 2005 (reference number: 05/NIR02/112).

**Study design**

Cluster randomised controlled trial (12 month duration)

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

This intervention aims to improve the psychoactive prescribing for residents in nursing homes. It is not disease specific.

**Interventions**

The intervention being tested is an adapted US model of pharmaceutical care - the Fleetwood model. This care model is provided to intervention home residents by pharmacists who have received specialist training in medicines for older people. It consists of monthly visits to nursing homes and includes the following steps:

1. Assessment of residents pharmaceutical care needs
2. Medication review
3. Preparation of a pharmaceutical care plan that is shared between the relevant healthcare personnel
4. Pharmacist intervention and direct communication with the prescriber

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

The primary outcomes for this trial will be a change in the prevalence of inappropriate psychoactive drug use and the number of residents who fall in the intervention homes compared to the control sites, over the 12 month study period. At three, six and 12 months, equivalent data as per baseline (excluding patient demographic data) will be collected using documentation provided by the US trial investigators and adapted for use in the present study, in addition to the number and length of pharmacist consultations (intervention group only).

### **Key secondary outcome(s)**

It has been shown that patients on psychoactive medication are more likely to fall, incurring additional costs to health care systems. Therefore, a secondary outcome of this study will be to examine and quantify the changes in resource usage as a result of the implementation of the modified Fleetwood model. Direct medical (healthcare) costs for both intervention and control patients will be calculated using the framework outlined by Drummond et al. (2000). The evaluation will be performed from the perspective of the payer: direct non-medical, indirect and intangible costs will not be estimated.

Cost estimates will be calculated using data collected at baseline and throughout the intervention period (e.g. hospitalisations, number of consultations), in conjunction with national accounting statistics representative of unit costs surveyed across the United Kingdom. The cost of patient drugs will be obtained from the standard Drug Tariff. Resource use data will be collected for 12 months prior to baseline and for 365 days (to standardise calculation of unit costs) after enrolment or until death. Mean annual cost estimates for each type of resource group will be shown separately (e.g. drug cost, hospitalisations, General Practitioner visits) and compared pre- and post-enrolment and by allocation to control or intervention group.

A secondary outcome to be evaluated in this study will be professional satisfaction of intervention prescribing support pharmacists, GPs and nurses (of intervention residents) with the programme. This will be assessed using postal questionnaires.

### **Completion date**

31/08/2007

## **Eligibility**

### **Key inclusion criteria**

Eleven matched pairs of nursing homes were selected at random from all those in Northern Ireland with greater than 30 beds, which consented to participate in the project. Within each home, all residents aged more than 65 years were invited to participate. Where appropriate, their next-of-kin were approached for consent to participate.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Senior

### **Sex**

All

**Key exclusion criteria**

Residents were excluded if they were terminally ill, in a coma or if no consent was obtained.

**Date of first enrolment**

01/04/2006

**Date of final enrolment**

31/08/2007

**Locations****Countries of recruitment**

United Kingdom

Northern Ireland

**Study participating centre**

School of Pharmacy

Belfast

United Kingdom

BT7 9BL

**Sponsor information****Organisation**

Queen's University Belfast (UK)

**ROR**

<https://ror.org/00hswnk62>

**Funder(s)****Funder type**

Government

**Funder Name**

Research and Development Office for the Health & Personal Social Services (UK) (reference no: EAT/2528/03)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 01/01/2010   |            | Yes            | No              |
| <a href="#">Results article</a> | results | 01/04/2011   |            | Yes            | No              |